For a research paper titled "Psychiatric comorbidity and its clinical specificity in fibromyalgia (FM): comparisons with low back pain (LBP)" within the scope of the P3 study, is it appropriate to use the International Classification of Diseases, 11th Revision (ICD‑11) criteria for diagnosing fibromyalgia (FM) and chronic low back pain (LBP), and are the Brief Pain Inventory – short form (BPI), the Toronto Alexithymia Scale (TAS‑20), and the Millon Clinical Multiaxial Inventory‑III (MCMI‑III) acceptable measurement tools?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Appropriateness of ICD-11 Criteria and Measurement Tools for FM vs. LBP Research

The ICD-11 criteria are acceptable for diagnosing FM and chronic LBP in this comparative research study, and the proposed measurement tools (BPI, TAS-20, MCMI-III) are appropriate for assessing psychiatric comorbidity and clinical specificity, though you should consider adding a somatization-specific measure given the evidence that somatization is the key differentiator between these conditions.

Diagnostic Criteria Assessment

ICD-11 for Fibromyalgia and Chronic LBP

The ICD-11 criteria are suitable for this research context, though you should be aware of evolving diagnostic frameworks:

  • For FM: While the EULAR guidelines 1 reference the American College of Rheumatology (ACR) criteria evolution (2010 criteria eliminated tender points and emphasized patient-reported somatic symptoms and cognitive difficulties), ICD-11 provides standardized diagnostic coding that aligns with contemporary understanding of FM as a centralized pain syndrome 2, 3

  • For chronic LBP: ICD-11 criteria are appropriate, though recent guidelines 4 show evolving recommendations toward simpler diagnostic triage systems (non-specific LBP with or without radicular pain versus serious pathology) rather than traditional three-category systems

  • Critical consideration: The diagnostic approach should account for overlap—approximately 25% of chronic LBP patients may transition to FM over time 5, and a distinct CLBP/FM+ subgroup exists 6

Measurement Tool Evaluation

Brief Pain Inventory - Short Form (BPI)

Appropriate and recommended. The BPI assesses pain intensity and interference with daily functioning, which are core outcomes emphasized in EULAR guidelines 1 for FM management evaluation. Pain is the dominant symptom in both conditions, making this tool essential for comparative analysis.

Toronto Alexithymia Scale (TAS-20)

Appropriate for psychiatric comorbidity assessment. This tool measures difficulty identifying and describing emotions, which relates to the cognitive dysfunction and mood disturbances characteristic of FM 2. However, it's not the most discriminating measure between FM and LBP.

Millon Clinical Multiaxial Inventory-III (MCMI-III)

Appropriate for comprehensive psychiatric assessment. The MCMI-III evaluates personality patterns and clinical syndromes, addressing the mood disturbances and psychiatric comorbidities common in FM 1, 2.

Critical Gap: Somatization Assessment

You should strongly consider adding a dedicated somatization measure. Recent high-quality evidence 7 demonstrates that somatization is the single most significant predictor distinguishing FM from LBP, with both the SCL-90R Somatization scale and QUISS showing strong discriminatory power (accuracy 74.3%, specificity 87.0%). This 2025 study found:

  • Somatization showed the largest standardized mean differences (SMD = -0.971) between FM and LBP
  • Somatization plus female sex predicted FM diagnosis with 65.3% positive predictive value
  • The FM phenotype is characterized not just by generalized painful loci but equally by generalized somatoform symptoms 7

Recommended Addition

Include either:

  • SCL-90R Somatization subscale, or
  • Quantification Inventory for Somatoform Syndromes (QUISS)

Both demonstrated equivalent discriminatory power (OR = 0.966 for each) 7.

Additional Considerations for Your Study Design

Fatigue and Sleep Assessment

The EULAR guidelines 1 identify fatigue and sleep disturbance as key outcomes alongside pain. Your current tools don't directly measure these domains, which are "common but not universal" in FM and have "important influence on quality of life" 1. Consider adding validated fatigue and sleep measures.

Physical Function Assessment

Recent evidence 6 shows individuals with FM engage less in high-intensity physical activities compared to those with CLBP. The EULAR guidelines 1 emphasize daily functioning as a core outcome. Your BPI captures pain interference with function, but a dedicated functional assessment tool would strengthen the study.

Cognitive Dysfunction

While the MCMI-III addresses some cognitive aspects, FM-specific cognitive difficulties (often called "fibro fog") 2, 3 may warrant dedicated assessment if cognitive specificity is a research focus.

Common Pitfalls to Avoid

  1. Overlooking the CLBP/FM+ subgroup: Approximately 25-39% of chronic LBP patients may have FM features 6, 5. Your diagnostic criteria should clearly differentiate pure LBP from this mixed phenotype.

  2. Underestimating somatization's role: Without measuring somatization, you may miss the primary distinguishing feature between these conditions 7.

  3. Ignoring sex differences: FM diagnosis is more frequent in women (83-96% in recent studies) 7, 6, and female sex is an independent predictor of FM versus LBP 7. Ensure adequate statistical power for sex-stratified analyses.

  4. Focusing solely on pain: While pain is dominant, the multidimensional nature of FM (fatigue, sleep, cognitive dysfunction) 1, 2 requires assessment beyond pain intensity and psychiatric comorbidity.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.